Dravet syndrome (sometimes called severe myoclonic epilepsy of infancy or SMEI) is a debilitating form of epilepsy that begins in infancy. The condition is very rare, affecting only 1 in every 20,000-40,000 births and can result in:

  • Seizures
  • Behavioral and developmental problems
  • Movement and balance issues
  • Language and speech problems
  • Growth issues
  • Sleeping difficulties
  • Frequent infections
  • Nervous system problems

Certain anti-seizure medications have helped some children and young adults reduce the number of seizures they have. But they don’t work for everyone. That’s why studies (like those in the FAiRE program) are so important.


The FAiRE (Fenfluramine Assessment in Rare Epilepsy) Dravet syndrome clinical studies are assessing whether an investigational drug called ZX008 can improve seizure control in children and young adults with Dravet syndrome (DS). Enrollment in the FAiRE DS studies is now closed. Results from the first study, Study 1, are available here. Results from the second study, Study 1504, will be available in the second half of 2018.

Visit www.clinicaltrials.gov to search for other studies for DS. Or join our mailing list and we'll keep you up-to-date about Zogenix's research.